Risks ID'd for Referral-Warranted Retinopathy of Prematurity

This article originally appeared here.
Share this content:
Risks ID'd for Referral-Warranted Retinopathy of Prematurity
Risks ID'd for Referral-Warranted Retinopathy of Prematurity

FRIDAY, Dec. 19, 2014 (HealthDay News) -- Predictors have been identified for referral-warranted (RW)-retinopathy of prematurity (ROP), according to research published online Dec. 18 in JAMA Ophthalmology.

Gui-Shuang Ying, Ph.D., from the University of Pennsylvania in Philadelphia, and colleagues examined predictive factors for the development of RW-ROP in a multicenter observational cohort.

The researchers found that 15.2 percent of the 979 infants without RW-ROP at first study-related eye examination who underwent at least two examinations developed RW-ROP. In multivariate analysis, the following were identified as significant predictors: male sex (odds ratio [OR], 1.80), nonblack race (OR, 2.76 for white; OR, 4.81 for other), low birth weight (OR, 5.16), younger gestational age (OR, 9.79), number of quadrants with preplus disease (OR, 7.12 for one to two quadrants; OR, 18.4 for three to four quadrants versus no preplus disease), stage 2 ROP (OR, 4.13), presence of retinal hemorrhage (OR, 4.36), the need for respiratory support (OR, 4.99 for controlled mechanical ventilator; OR, 11.0 for high-frequency oscillatory ventilation), and slow weight gain (OR, 2.44). The development of RW-ROP was predicted significantly better with these characteristics than with birth weight and gestational age (area under the receiver operating characteristic curve, 0.88 versus 0.78; P < 0.001).

"Using a model like the one presented here could help identify lower-risk infants who are less likely to develop RW-ROP and require less-frequent imaging or eye examinations," the authors write.

One author disclosed financial ties to Janssen Research and Development.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters




More in Home

FDA Approves Palynziq for Phenylketonuria

FDA Approves Palynziq for Phenylketonuria

Drug is a novel enzyme therapy for adult patients with PKU with uncontrolled blood Phe concentrations

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in proportion of adults recommended for treatment; estimated decrease in CVD events, deaths